Effect of prolonged hydroxytamoxifen treatment of MCF‐7 cells on mitogen activated kinase cascade
Open Access
- 6 February 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 98 (5), 698-706
- https://doi.org/10.1002/ijc.10252
Abstract
Resistance to the antiestrogen tamoxifen is the main stumbling block for the success of breast cancer therapy. We focused our study on cellular alterations induced by a prolonged treatment with the active tamoxifen metabolite hydroxytamoxifen (OHT). We show that a prolonged OHT treatment (for up to 7 days) led to a progressive increase in the level of phosphorylated p44/42 mitogen activated kinase (MAP kinase) induced by 10−7 M TPA stimulation, without any significant change in the protein level. This effect was also observed in MCF‐7 cells grown first in medium containing dextran‐coated charcoal‐treated FCS (DCC medium) for 20 days prior to OHT treatment, indicating a specific effect of the antiestrogen and not an effect of estrogen deprivation. It was prevented by cotreatment with estradiol and not observed in the estrogen receptor negative HeLa cell line, suggesting that it was mediated by the estrogen receptor. TPA induced phosphorylation of MEK1/2 was also raised by OHT treatment, without any change in their protein level or Raf‐1 and H‐Ras levels. When the MCF‐7R OHT resistant cell line was grown in antiestrogen containing medium, the level of phosphorylated p44/42 MAP kinase was also high but reversed when the antiestrogen was removed. The 2 other MAP kinase, JNK and P38 pathways were not affected in the same way by OHT treatment. In conclusion, our data reveal that a prolonged OHT treatment, by increasing p44/42 MAPK activity, affects a key step in the growth control of MCF‐7 cells, although not sufficiently to overcome the growth inhibitory effect of the drug.Keywords
This publication has 39 references indexed in Scilit:
- Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer CellsPublished by Elsevier BV ,2001
- MEKK1 Activation of Human Estrogen Receptor and Stimulation of the Agonistic Activity of 4-Hydroxytamoxifen in Endometrial and Ovarian Cancer CellsMolecular Endocrinology, 2000
- cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotypeOncogene, 1999
- Convergence of Progesterone with Growth Factor and Cytokine Signaling in Breast CancerPublished by Elsevier BV ,1998
- Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cellsInternational Journal of Cancer, 1998
- Mitogenic Signaling of Insulin-like Growth Factor I in MCF-7 Human Breast Cancer Cells Requires Phosphatidylinositol 3-Kinase and Is Independent of Mitogen-activated Protein KinasePublished by Elsevier BV ,1997
- Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylationMolecular Endocrinology, 1995
- Protein Kinase C-Dependent and -Independent Pathways Mediate Epidermal Growth Factor (EGF) Effects in Human Endometrial Adenocarcinoma Cell Line KLEGynecologic Oncology, 1994
- Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: Alterations of growth factor receptor binding sites and tyrosine kinase activityBiochemical and Biophysical Research Communications, 1990
- Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogensBiochemical and Biophysical Research Communications, 1987